GIOVANNI SCHIFITTO, MD
Psychiatric at Elmwood Ave, Rochester, NY

License number
New York 215806
Category
Psychiatric
Type
Vascular Neurology
Address
Address
601 Elmwood Ave, Rochester, NY 14642
Phone
(585) 275-4423
(585) 473-4678 (Fax)

Personal information

See more information about GIOVANNI SCHIFITTO at radaris.com
Name
Address
Phone
Giovanni Schifitto, age 64
2 Evandale Rd, Rochester, NY 14618
Giovanni Schifitto, age 65
2 Evandale Rd, Rochester, NY 14618

Organization information

See more information about GIOVANNI SCHIFITTO at bizstanding.com

Giovanni Schifitto MD

601 Elmwood Ave, Rochester, NY 14642

Industry:
Neurologist
Phone:
(585) 275-3052 (Phone)
Giovanni Schifitto

Professional information

See more information about GIOVANNI SCHIFITTO at trustoria.com
Giovanni Schifitto Photo 1
Dr. Giovanni Schifitto, Rochester NY - MD (Doctor of Medicine)

Dr. Giovanni Schifitto, Rochester NY - MD (Doctor of Medicine)

Specialties:
Neuropsychiatry (Neurology)
Address:
University-Rochester Medical
601 Elmwood Ave, Rochester 14642
(585) 275-0558 (Phone)
Certifications:
Neurology, 1995
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
University-Rochester Medical
601 Elmwood Ave, Rochester 14642
Strong Memorial Hospital
601 Elmwood Ave, Rochester 14642
Education:
Residency Hospital
Mt Sinai School Of Med
Strong Mem Hsp University Rochester


Giovanni Schifitto Photo 2
Treatment Of Neuroads Using Inhibitors Of Glycogen Synthase Kinase (Gsk)-3

Treatment Of Neuroads Using Inhibitors Of Glycogen Synthase Kinase (Gsk)-3

US Patent:
2009008, Mar 26, 2009
Filed:
Dec 19, 2006
Appl. No.:
12/158896
Inventors:
Harris A. Gelbard - Pittsford NY, US
Sanjay B. Maggirwar - Rochester NY, US
Stephen Dewhurst - Rochester NY, US
Giovanni Schifitto - Rochester NY, US
International Classification:
A61K 33/00, A61K 31/55, A61K 31/19
US Classification:
424722, 514215, 514557
Abstract:
Provided is a method of treating or preventing neurological disease in a subject in need of such treatment or prevention, comprising administering to the subject a therapeutically effective dose of a GSK-3 inhibitor.